UK’s New International Recognition Procedure A ‘Win-Win’ For Stakeholders

Companies wanting to use the new accelerated procedure will be paying more than £68,000 for the privilege, and will have to inform the UK medicines agency of any divergent decisions by reference regulators.

electronically connected globe (shutterstock)
Shutterstock • Source: Shutterstock

From 1 January, pharmaceutical companies seeking a marketing authorization from the UK regulator, the MHRA, can use the new International Recognition Procedure (IRP), under which the MHRA will be able to take account of approval decisions taken by seven other world regulators.

The IRP, which is intended to accelerate assessments at the MHRA, offers two routes to approval, Recognition A and Recognition...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United Kingdom

More from Europe